ArticleTrends in molecular medicine2016
Combinatorial Antigen Targeting: Ideal T-Cell Sensing and Anti-Tumor Response.
Article in Trends in molecular medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Emerging roles of Notch signaling in the tumor microenvironment of digestive system cancers.Frontiers in molecular biosciences · 2026Review
- Neoantigen-driven personalized tumor therapy: An update from discovery to clinical application.Chinese medical journal · 2025Review
- Engineering innate immune cells for cancer immunotherapy.Nature biotechnology · 2025Review
- CAR-T cells neurotoxicity from consolidated practice in hematological malignancies to fledgling experience in CNS tumors: fill the gap.Frontiers in oncology · 2023Review
- Engineering CAR T cells for enhanced efficacy and safety.APL bioengineering · 2022Review
- Control of the activity of CAR-T cells within tumours via focused ultrasound.Nature biomedical engineering · 2021Article
- CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities.Cellular oncology (Dordrecht, Netherlands) · 2021Review
- Chimeric Antigen Receptor T Cell Therapy for Solid Tumors: Current Status, Obstacles and Future Strategies.Cancers · 2019Review
- New Chimeric Antigen Receptor Design for Solid Tumors.Frontiers in immunology · 2017Review
- Chimeric antigen receptors: driving immunology towards synthetic biology.Current opinion in immunology · 2016Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
T cells expressing chimeric antigen receptors (CARs) are a formidable platform for the study and application of synthetic biology approaches to study customized and flexible control of cellular functions. Recent reports in the journal Cell provide a new twist on combinatorial antigen targeting, profiting from the singular cleavage and signaling of the Notch receptor to conditionally express CARs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.